- Home
- JRS vs CRBP Comparison
JRS vs CRBP Comparison
Compare JRS & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JRS | CRBP |
|---|---|---|
| Founded | 2001 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 210.6M | 190.3M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | JRS | CRBP |
|---|---|---|
| Price | $7.35 | $4.48 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $34.03 |
| AVG Volume (30 Days) | 72.7K | ★ 783.3K |
| Earning Date | 01-01-0001 | 11-11-2026 |
| Dividend Yield | ★ 8.87% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,822,272.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $116.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 97.62 |
| 52 Week Low | $7.12 | $4.22 |
| 52 Week High | $8.90 | $19.35 |
Technical Indicators
Market Signals| Indicator | JRS | CRBP |
|---|---|---|
| Relative Strength Index (RSI) | 35.20 | 21.31 |
| Support Level | $7.12 | N/A |
| Resistance Level | $7.49 | $9.66 |
| Average True Range (ATR) | 0.12 | 0.40 |
| MACD | 0.03 | -0.05 |
| Stochastic Oscillator | 16.64 | 9.11 |
Price Performance
Historical ComparisonAbout JRS Nuveen Real Estate Income Fund of Beneficial Interest
Nuveen Real Estate Income Fund is a diversified closed-end investment company. The Fund s investment objective is to provide total return through high current income and capital appreciation.
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.